Litigation Details for OTSUKA PHARMACEUTICAL CO., LTD. v. SUN PHARMACEUTICAL INDUSTRIES LTD. (D.N.J. 2014)

OTSUKA PHARMACEUTICAL CO., LTD. v. SUN PHARMACEUTICAL INDUSTRIES LTD. (D.N.J. 2014)

Docket	1:14-cv-04307	Date Filed	2014-07-07
Court	District Court, D. New Jersey	Date Terminated	2016-03-10
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand	None	Referred To	Karen M. Williams
Patents	8,017,615; 8,580,796; 8,642,760
Link to Docket	External link to docket

Details for OTSUKA PHARMACEUTICAL CO., LTD. v. SUN PHARMACEUTICAL INDUSTRIES LTD. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-07				External link to document

Litigation summary and analysis for: OTSUKA PHARMACEUTICAL CO., LTD. v. SUN PHARMACEUTICAL INDUSTRIES LTD. (D.N.J. 2014)

Last updated: July 27, 2026

Otsuka Pharmaceutical v. Sun Pharma (1:14-cv-04307): Litigation Summary, Patent Issues, and Exclusivity/Launch Risk

Otsuka Pharmaceutical Co., Ltd. sued Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of New Jersey under the Hatch-Waxman framework in case 1:14-cv-04307 (filed 2014). The dispute is tied to Sun’s FDA ANDA referencing an Otsuka brand drug and centers on Hatch-Waxman patent infringement tied to Orange Book-listed patents.

Actionable bottom line: this case is an early-generation Hatch-Waxman suit that typically determines (1) which Orange Book patents are adjudicated, (2) whether the generic can launch at risk, and (3) whether a settlement or agreed launch date is reached. Without the patent list and court filings in the docket text, it is not possible to state which specific Otsuka patents were asserted, the legal theories (literal infringement, induced, willful), or the resulting claim construction, injunction, or final judgment.

What patents were asserted in Otsuka v. Sun Pharma 1:14-cv-04307 and what was the claim scope?

Direct answer: Not determinable from the provided case identifier alone. The docket number 1:14-cv-04307 identifies the lawsuit, but the specific asserted patents, claims, Hatch-Waxman certifications, and infringement theories require the complaint and/or infringement contentions and the patents-in-suit.

Which Orange Book patents usually drive Hatch-Waxman complaints like this?

In Otsuka-led Hatch-Waxman actions, asserted patents most commonly fall into these buckets:

• Formulation/composition of matter patents (drug substance or excipient systems)
• Method-of-use patents (therapeutic regimen claims)
• Manufacturing/solid-state or process patents (API or formulation processes)
• Device or delivery system patents (if applicable to the reference product)

What certifications and defenses usually matter?

The infringement issues usually map to:

• Paragraph I/II/III/IV certifications (non-infringement or invalidity)
• Non-infringement by design-around (generic product differences)
• Invalidity arguments (anticipation/obviousness, indefiniteness, lack of enablement)
• Induced/willful infringement allegations if specific intent evidence is pled

What was the procedural posture in 1:14-cv-04307 (motions, hearings, and outcomes)?

Direct answer: Not determinable from the provided case identifier alone. The procedural posture depends on:

• whether the case went to Markman claim construction
• whether summary judgment issued
• whether a stipulated dismissal occurred after settlement
• whether there was a permanent injunction or temporary TRO/preliminary injunction
• whether the court addressed ATD/Ashcroft issues or other threshold procedural defenses

Typical milestones in Hatch-Waxman litigation

A case like this often follows a timeline:

• complaint and initial responsive pleadings
• infringement/invalidity contentions
• Markman scheduling
• expert discovery and claim construction
• dispositive motion(s)
• settlement or judgment

Did Otsuka v. Sun Pharma 1:14-cv-04307 settle, and what launch date risk did it create?

Direct answer: Not determinable from the provided case identifier alone. Settlement outcomes in this case category can include:

• a worldwide or U.S.-only settlement
• a design-around commitment
• an agreed entry date tied to specific patent expirations
• a license (rare compared with “no-launch-before” settlements, but occurs)
• dismissal with stipulated terms governing sale of the ANDA product

What settlement terms typically affect exclusivity exposure

If a settlement exists, it usually dictates:

• the earliest permissible U.S. launch date
• whether launch is permitted “at risk” after certain patent expirations
• whether sales are restricted to certain dosages/strengths
• whether future certifications are limited

When does the reference product exclusivity end, and how does this case change generic entry timing?

Direct answer: Not determinable from the provided case identifier alone because the reference product name and regulatory pathway are not specified.

Key exclusivity layers that drive timing

Generic launch timing generally depends on:

• 5-year exclusivity for first-in-class/first-filing drug
• 7-year exclusivity for new chemical entity plus additional criteria
• patent term under 35 U.S.C. 154 and any PTA
• pediatric exclusivity adjustments (if any)
• Orange Book listed patent expirations and any “triggering” patents used in the litigation

What is the Orange Book status for the Otsuka reference drug at issue in 1:14-cv-04307?

Direct answer: Not determinable from the provided case identifier alone because the Orange Book drug name and the Orange Book patent list are not provided.

What you need to know to assess Orange Book status

Orange Book status analysis requires:

• active ingredient(s)
• dosage form(s)
• listed patents by type: drug substance, drug product, method
• patent expiration and any pediatric/other extensions
• which patents are the “in-suit” patents in the complaint

How strong is the patent estate for Otsuka versus Sun’s ANDA risk in this case?

Direct answer: Not determinable from the provided case identifier alone because patent strength requires:

• the list of patents asserted
• claim scope and asserted independent claims
• file history and prosecution history relevant to validity and construction
• the asserted product’s structural and functional correspondence

How courts typically score patent strength in Hatch-Waxman

Even absent a full merits decision, litigation strength often correlates to:

• whether claims survive a Markman construction and are not narrowed out
• whether invalidity arguments rely on close prior art
• whether a generic is close enough to satisfy infringement under the construed claims

What generic entry risks existed for Sun Pharma after 1:14-cv-04307 (at-risk launch, design-arounds, and Section 271)?

Direct answer: Not determinable from the provided case identifier alone. Entry risk depends on:

• whether an injunction issued
• which patents were held not infringed or invalid
• whether a settlement set an entry date and what products/dosages it covered

Risk scenarios in the generic launch window

Common post-suit outcomes:

• dismissal with no restriction (rare)
• injunction until later patent expiry
• carve-outs permitting some strengths/dosages
• design-around that avoids an asserted claim element
• settlement date that prevents entry before a defined trigger

Which legal issues did Otsuka raise (infringement, invalidity, inequitable conduct, standing) and how do they usually play out?

Direct answer: Not determinable from the provided case identifier alone because the specific pleaded legal theories are not provided.

Most frequent litigated issues in these Otsuka-type ANDA disputes

• non-infringement positions based on ANDA labeling and composition
• invalidity based on anticipation/obviousness and enablement
• procedural defenses and jurisdictional disputes tied to standing or certification
• alleged inducement for label-directed infringement where product labeling matches method claims

How does Otsuka v. Sun Pharma 1:14-cv-04307 compare with other Otsuka Hatch-Waxman litigations?

Direct answer: Not determinable from the provided case identifier alone. Comparative analysis requires:

• the asserted product(s)
• patent families and expiry dates
• settlement patterns and results across the relevant portfolio

Key Takeaways

• Case: Otsuka Pharmaceutical Co., Ltd. v. Sun Pharmaceutical Industries Ltd., 1:14-cv-04307.
• Type of dispute: Hatch-Waxman ANDA patent litigation (inferred from the party pattern and case context, but specific asserted patents and outcomes are not provided here).
• What cannot be stated from the identifier alone: asserted patent numbers, claim scope, legal theories, procedural outcomes, settlement terms, and the resulting U.S. launch timing.

FAQs

1. What is the usual relief sought by branded innovators in Hatch-Waxman suits like 1:14-cv-04307?
2. How do courts decide whether generic ANDA products infringe method-of-use versus formulation claims?
3. When settlements occur, what clauses most affect generic launch timing and design-around scope?
4. How do pediatric exclusivity and patent term adjustment change the effective entry date after a generic suit?
5. What evidence supports induced infringement allegations tied to ANDA labeling in method claims?

References

1. U.S. District Court docket entry for Otsuka Pharmaceutical Co., Ltd. v. Sun Pharmaceutical Industries Ltd., 1:14-cv-04307.